Why Peptides Degrade: The Chemistry Behind Storage and Shelf Life

"Store cold, keep it dry, protect it from light" is repeated on every peptide vendor page. It is rarely explained. The explanation is the useful part — because once you know which reactions actually degrade a peptide, you can see why the same advice matters enormously for one sequence and hardly at all for another.

Degradation is several reactions, not one#

The word "degraded" hides a lot. A peptide can lose activity through at least six distinct chemical routes and one physical one, and they have different triggers, different rates and different products.

Pharmaceutical scientists have mapped these pathways for decades. A standard review of the field covers chemical instability and physical instability separately, along with how the two feed each other — a chemically modified molecule often becomes more prone to aggregation^[1].

Here is what each route actually is.

Deamidation. Asparagine and glutamine each carry an amide group on their side chain. That group can be lost, converting the residue to aspartate or glutamate. This changes the molecule's charge.

Hydrolysis. A peptide bond is broken by water, cutting the chain. Bonds next to aspartate are particularly vulnerable, especially at low pH.

Oxidation. Sulfur- and ring-containing residues — methionine, cysteine, tryptophan, and to a lesser extent histidine and tyrosine — react with oxygen species and pick up oxygen atoms.

Disulfide scrambling. In a peptide with more than one cysteine, existing disulfide bridges can break and re-form in the wrong pairing, producing a molecule with the right mass but the wrong shape.

Diketopiperazine formation. The first two residues can cyclise and snip themselves off the N-terminus. Sequences with glycine in the third position are especially prone to it.

Racemization. An amino acid flips from the L form to the D form. The mass is unchanged; the three-dimensional shape is not.

Aggregation. Not a chemical reaction at all. Molecules clump together. No bond in the chain has changed, but the material may no longer behave the same way — and aggregates are a known immunogenicity concern in protein drug development.

Deamidation, in detail, because it is the fast one#

Deamidation deserves a closer look, because the rate can be surprising.

The reaction does not usually go directly. The asparagine side chain attacks the backbone to form a five-membered ring called a succinimide, and that ring then opens. It can open two ways, giving either normal aspartate or isoaspartate, where the backbone now runs through the side chain instead. The same intermediate also allows racemization.

The classic measurement comes from Geiger and Clarke, who ran synthetic model peptides in buffer and followed the chemistry directly. The hexapeptide Val-Tyr-Pro-Asn-Gly-Ala deamidated with a half-life of about 1.4 days at 37 °C and pH 7.4^[2].

Two things about that number.

It is a worst case by design. Asn-Gly is the fastest-deamidating pair known, because the small glycine leaves the backbone free to fold into the ring. Swap the glycine for something bulky and the rate falls by orders of magnitude.

And it was measured in solution, at body temperature, at neutral pH. A dry powder in a freezer is a completely different chemical environment. But it demonstrates the principle cleanly: given the right sequence and the right conditions, a peptide can measurably change in days, with no bacteria, no light and nothing visibly wrong with the vial.

Oxidation is usually catalysed, not spontaneous#

Methionine sitting in a sealed vial does not simply react with air on its own at any useful rate. It needs help.

Model-peptide work showed that methionine oxidises to methionine sulfoxide in the presence of transition metal ions, oxygen and an electron donor, and that the dominant oxidising species changes with pH — hydrogen peroxide at or below neutral, metal-bound reactive oxygen species above it^[4]. The broader review of oxidation mechanisms in protein pharmaceuticals reaches the same practical conclusion: contaminating oxidants, trace transition metals and light are the drivers^[3].

This is why real pharmaceutical formulations contain things that look unrelated to the active molecule. Metal chelators are there to lock up trace iron and copper. Amber glass and secondary packaging are there for light. Nitrogen headspace is there for oxygen. Each one is aimed at a specific catalyst.

It also explains a common source of confusion. Two vials of the same peptide, stored identically, can oxidise at different rates if one picked up more trace metal contamination during manufacture. The variable is not the storage. It is what was in the vial to begin with.

Why dry matters more than cold#

Freeze-drying is not about temperature. It is about removing the reactant and the medium.

Hydrolysis consumes water directly. Deamidation needs it. And beyond being a reactant, water is what gives molecules the mobility to move, meet and react at all. Take it away and most of the chemistry slows dramatically.

But "dry" turns out to be the wrong word for what matters. Recent work on lyophilized formulations found that water activity — a measure of how chemically available the remaining water is, rather than how much of it there is — is the better indicator of storage stability^[5].

The distinction is real. Water bound tightly into a sugar glass is not doing the same thing as the same mass of water free to move. This is why the excipients in a freeze-dried formulation — sucrose, trehalose, mannitol — are not filler. They form the amorphous solid that immobilises both the peptide and the residual water.

Two related points follow. Moisture that gets back in undoes the work, which is why peptides with many charged residues — the ones that readily pull water from the air — are the ones supplier documentation flags for desiccated storage^[7]. And repeated freeze-thaw cycling is a known stress in laboratory practice, which is why lab reagent guidance describes aliquoting a stock rather than repeatedly warming and refreezing the whole thing^[8].

What a real stability study looks like#

Here is where the chemistry meets the paperwork, and where most retail claims quietly stop.

A shelf life for an approved drug is not an estimate. It is the output of a study designed to a published standard. ICH Q1A(R2), adopted by the FDA as guidance in 2003, specifies the conditions: long-term storage at 25 °C ± 2 °C and 60% relative humidity ± 5% (or 30 °C / 65% RH) for at least 12 months, plus accelerated testing at 40 °C ± 2 °C and 75% RH ± 5% for six months^[6].

Three features of that design are worth naming.

Humidity is controlled, not just temperature. Given that water activity governs solid-state stability, a study that fixed only temperature would be measuring the wrong variable.

The methods have to be stability-indicating. A test that still shows the main peak while a degradation product accumulates underneath it has not measured stability. The assay must resolve the specific products the chemistry predicts.

Degradation products are treated as impurities. They are identified and controlled, not written off, because a modified peptide can differ in potency and in immunogenicity from the intended one.

The asymmetry is the whole point. Degradation chemistry does not care how a product is labelled. It proceeds identically in a regulated vial and an unregulated one. The difference is only whether anyone measured it.

The honest conclusion#

Peptide stability is one of the few areas in this field where the science is genuinely settled. The reactions are known, their triggers are known, and the methods for detecting them are standard.

That makes it a useful test to apply. When a product carries a storage instruction and a shelf life but no stability data, the chemistry has not been suspended — it has just gone unmeasured. And an unmeasured degradation pathway is not the same thing as an absent one.

Where to go next#

• Why a 10 mg peptide vial does not contain 10 mg of peptide — purity, content, and the mass a certificate does not report.
• Peptide purity, contamination, and the limits of a certificate of analysis — the five things a CoA cannot tell you.
• How to read peptide research without falling for marketing — study types and the animal-to-human gap.

Advertising disclosure: ads on this page are for NuNu Research, a research-use-only chemical storefront that shares an owner with PeptidesInfo. Ads never influence the evidence grades, regulatory statuses, or conclusions above, which come solely from the cited primary sources.